Dr. Sam Suman Nuthalapaty, MD

Dr. Nuthalapaty practices at Sherman Oaks Hospital in Sherman Oaks, California, part of Prime Healthcare Services.

Dr. Nuthalapaty's NPI, 1972758787, was assigned on November 20, 2008. Dr. Nuthalapaty holds Connecticut license 049139.

Dr. Nuthalapaty's primary practice is Sherman Oaks Hospital, at 4929 Van Nuys Blvd, Sherman Oaks, CA 91403 in Los Angeles County. The practice phone is (818) 981-7111.

Dr. Nuthalapaty's primary practice is Sherman Oaks Hospital in Sherman Oaks, California, part of Prime Healthcare Services. Dr. Nuthalapaty is also affiliated with Encino Hospital Medical Center. The medical group on file is Epic Medical Group. Dmand AI also links Dr. Nuthalapaty to 5 more skilled nursing facilities, 2 home health agencies, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nuthalapaty practices, 11 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Nuthalapaty's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Nuthalapaty's licenses on file in 2 states: Connecticut and New York.

CMS data shows 3,676 Medicare services from Dr. Nuthalapaty across 11 procedure codes in 2024, for 752 Medicare patients. Medicare paid $317,959 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 752 Medicare patients who saw Dr. Nuthalapaty in 2024. The largest group is 75 to 84, with 250 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 79% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nuthalapaty's median patient age at 72, with 49% women.

In 2024, Dr. Nuthalapaty wrote 7,891 Medicare Part D claims for 235 patients. 85% of them were for generic drugs. CMS names the drug for 7,263 of them, across 135 drugs with 11 or more claims each, at $499,461 in total drug cost. In 2023, CMS named 9,099 claims across 152 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Nuthalapaty for performance year 2024, reported individually. Dr. Nuthalapaty accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 22 general payments to Dr. Nuthalapaty from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Sun Pharmaceutical Industries Inc. paid the most, $158.